Greenland Mines (GRML) vs MiNK Therapeutics (INKT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
MiNK Therapeutics (INKT) has outperformed Greenland Mines (GRML) over the past year, losing 26.3% versus a loss of 83.3%. Greenland Mines is the larger company by market cap ($69.0 million vs $54.7 million), about 1.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GRML | INKT |
|---|---|---|
| Share price | $5.17 | $10.72 |
| Market cap | $69.00M | $54.70M |
| 1-day change | -12.07% | -2.55% |
| YTD return | -64.22% | -3.86% |
| 1-year return | -83.30% | -26.32% |
| 5-year return | — | -91.07% |
| EPS (TTM) | $-9.74 | $-2.39 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $37.00 | $16.93 |
| 52-week low | $2.82 | $8.48 |
| Distance from 52-week high | -86.03% | -36.67% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +2027.66% | +263.81% |
| Average volume | 7.92M | 13.73K |
| Shares outstanding | 13.35M | 5.10M |
| Employees | 5 | 15 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- INKT has outperformed GRML by 57.0 percentage points over the past year.
About Greenland Mines
GRML stock →Greenland Mines Ltd engages in the cell and gene therapy, and natural resources businesses. The company primarily explores palladium, gold, and platinum deposits.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 5 employees
About MiNK Therapeutics
INKT stock →MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, manufacture, and commercialization of allogeneic, off-the-shelf, and invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company develops agenT-797, an off-the-shelf, allogeneic, and native iNKT cell therapy that is in Phase 2 clinical trial for the clinical safety and efficacy of the combination of agenT-797, botensilimab and balstilimab with ramucirumab and paclitaxel for patients with previously treated, advanced esophageal, gastric, or gastroesophageal junction adenocarcinoma; Phase 1 trial as a monotherapy in combination with anti-PD-1 checkpoint inhibitors, pembrolizumab, and nivolumab for refractory solid tumor cancers; and Phase 1 trial for the treatment of moderate to severe viral acute respiratory distress syndrome (ARDS).
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 15 employees
GRML vs INKT FAQ
Which is bigger, Greenland Mines or MiNK Therapeutics?
Greenland Mines (GRML) is larger, with a market capitalization of $69.00M compared with $54.70M for MiNK Therapeutics (INKT).
Which stock has performed better over the past year, GRML or INKT?
INKT returned -26.32% over the past 12 months, compared with -83.30% for GRML (price return, excluding dividends). Past performance does not predict future results.
Are Greenland Mines and MiNK Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.